One of such functions was recently demonstrated in triple-negative BCs, where ARF collaborates with TP53 to suppress a tumor-promoting inflammatory pathway involving interferon-β and STAT1, which are also important factors in ADAR-mediated RNA editing (90, 93, 132, 175). This evidence concerns the gene ADAR and neoplasm.